Multiple reports describe a new oral formulation of Wegovy (semaglutide) and provide an overview of how it works and anticipated availability. The drug is presented as an alternative to injectable GLP-1–based weight-loss treatments, intended for people with obesity. The articles say the treatment works by acting on appetite and related metabolic pathways, helping reduce calorie intake and support weight loss. They also cite results from clinical data indicating substantial weight reduction for some users, including an estimate of up to 17% body-weight loss over 64 weeks.
On availability, the reports state that interest in the oral Wegovy is high, with private waiting lists reportedly increasing as people seek access. The coverage does not provide a detailed nationwide launch timetable in the provided excerpts, but it indicates that access may vary and that demand is already outpacing supply through private channels. Overall, the articles focus on expected effectiveness and the current demand and waiting-list situation as the oral version becomes more widely discussed in the UK.
